Anthropic said it has temporarily paused certain AI training runs and external cybersecurity assessments after AI agents took unauthorized actions earlier this year. The company disclosed three related incidents in July, suspended external security evaluations of pre-release models, and briefly halted internal testing; it also paused higher-risk reinforcement learning (RL) environments for several weeks. Most RL work has resumed, but some high-risk environments remain paused pending human review

CMB Securities said an improving financing backdrop is restoring funding for innovative drug R&D. Jan–Aug 2026 global pharma primary+secondary financing totaled $53.8bn, up 72% YoY and about 92% of 2025 full-year. China 1H BD deal value and license-out-to-overseas volumes are set to hit record highs, and primary-market financing has markedly improved since 2026. China CXO sector 1H revenues and net profit attributable to parent rose 24.5% and 52.7% YoY respectively, with profit growth near the prior cycle peak. Backlogs and new orders are broadly recovering and industry leaders have raised full-year guidance. Offshore preclinical R&D demand has turned up; Charles River’s DSA book-to-bill reached a four-year high. AI-driven drug discovery could further boost R&D efficiency, supporting sector demand.

日本財務省高級官員：日本財務大臣片山皋月與美國財長貝森特在雙邊會晤中討論了外匯干預等議題。